ALX Oncology (ALXO) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Atrium Therapeutics is the larger company by market cap ($149.3 million vs $137.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | RNA |
|---|---|---|
| Share price | $1.06 | $6.92 |
| Market cap | $137.03M | $149.27M |
| 1-day change | +3.92% | -0.86% |
| YTD return | -6.19% | — |
| 1-year return | -25.87% | — |
| 5-year return | -96.84% | — |
| EPS (TTM) | $-0.87 | $-5.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-101.69M | — |
| 52-week high | $2.66 | $16.77 |
| 52-week low | $0.862 | $6.36 |
| Distance from 52-week high | -60.15% | -58.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +333.96% | +217.92% |
| Average volume | 1.19M | 297.20K |
| Shares outstanding | 129.27M | 21.57M |
| Employees | 49 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
ALXO vs RNA FAQ
Which is bigger, ALX Oncology or Atrium Therapeutics?
Atrium Therapeutics (RNA) is larger, with a market capitalization of $149.27M compared with $137.03M for ALX Oncology (ALXO).
Are ALX Oncology and Atrium Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.